References
- Nebert DW, Zhang G, Vesell ES. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab Rev. 2008;40(2):187–224. doi:10.1080/03602530801952864.
- Lee JW, Aminkeng F, Bhavsar AP, et al. The emerging era of pharmacogenomics: current successes, future potential, and challenges. Clin Genet. 2014;86(1):21–28. doi:10.1111/cge.12392.
- Guo C, Xie X, Li J, et al. Pharmacogenomics guidelines: current status and future development. Clin Exp Pharmacol Physiol. 2019;46(8):689–693. doi:10.1111/1440-1681.13097.
- Pearson ER. Diabetes: is there a future for pharmacogenomics guided treatment? Clin Pharmacol Ther. 2019;106(2):329–337. doi:10.1002/cpt.1484.
- Kaye AD, Koress CM, Novitch MB, et al. Pharmacogenomics, concepts for the future of perioperative medicine and pain management: a review. Best Pract Res Clin Anaesthesiol. 2020;34(3):651–662. doi:10.1016/j.bpa.2020.07.004.
- Linder MW, Prough RA, Valdes R. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin Chem. 1997;43(2):254–266. doi:10.1093/clinchem/43.2.254.
- Kalow W, Genest K. method for the detection of atypical forms of human serum cholinesterase. DETERMINATION OF dibucaine numbears. Can J Biochem Physiol. 1957;35(6):339–346. doi:10.1139/y57-041.
- Vesell ES, Page JG. Genetic control of drug levels in man: antipyrine. Science. 1968;161(3836):72–73. doi:10.1126/science.161.3836.72.
- Vesell ES, Page JG. Genetic control of dicumarol levels in man. J Clin Invest. 1968;47(12):2657–2663. doi:10.1172/JCI105949.
- Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev. 2006;58(3):521–590. doi:10.1124/pr.58.3.6.
- Weinshilboum R, Wang L. Pharmacogenomics: bench to bedside. Nat Rev Drug Discov. 2004;3(9):739–748. doi:10.1038/nrd1497.
- Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343–350. doi:10.1038/nature15817.
- Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician’s guide to terminology, documentation, and reporting. Ann Intern Med. 2004;140(10):795–801. doi:10.7326/0003-4819-140-10-200405180-00009.
- Centers for Disease Control and Prevention. CDC: adverse Drug Events in Adults [Internet]. 2017. https://www.cdc.gov/medicationsafety/adult_adversedrugevents.html
- Sharp CN, Linder MW, Valdes R. Polypharmacy: a healthcare conundrum with a pharmacogenetic solution. Crit Rev Clin Lab Sci. 2019;57(3):161–180. doi:10.1080/10408363.2019.1678568.
- Berm EJJ, de Looff M, Wilffert B, et al. Economic evaluations of pharmacogenetic and pharmacogenomic screening tests: a systematic review. Second update of the literature. PLoS One. 2016;11(1):e0146262. doi:10.1371/journal.pone.0146262.
- El Morabet N, Uitvlugt EB, van den Bemt BJF, et al. Prevalence and preventability of Drug-Related hospital readmissions: a systematic review. J Am Geriatr Soc. 2018;66(3):602–608. doi:10.1111/jgs.15244.
- Barr M, Rose D. The great ambivalence: factors likely to affect service user and public acceptability of the pharmacogenomics of antidepressant medication. Sociol Health Illn. 2008;30(6):944–958. doi:10.1111/j.1467-9566.2008.01116.x.
- Drozda K, Pacanowski MA. Clinical trial designs to support clinical utility of pharmacogenomic testing. Pharmacother J Hum Pharmacol Drug Ther. 2017;37(9):1000–1004. doi:10.1002/phar.1971.
- Liko I, Lee YM, Stutzman DL, et al. Providers’ perspectives on the clinical utility of pharmacogenomic testing in pediatric patients. Pharmacogenomics. 2021;22(5):263–274. doi:10.2217/pgs-2020-0112.
- Hippman C, Nislow C. Pharmacogenomic testing: clinical evidence and implementation challenges. J Pers Med. 2019;9(3):40. doi:10.3390/jpm9030040.
- U.S. Food and Drug Administration. FDA: table of Pharmacogenomic Biomarkers in Drug Labeling. 2022. https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling
- Vo TT, Bell GC, Owusu Obeng A, et al. Pharmacogenomics implementation: considerations for selecting a reference laboratory. Pharmacotherapy. 2017;37(9):1014–1022. doi:10.1002/phar.1985.
- Volpi S, Bult CJ, Chisholm RL, et al. Research directions in the clinical implementation of pharmacogenomics: an overview of US programs and projects. Clin Pharmacol Ther. 2018;103(5):778–786. doi:10.1002/cpt.1048.
- Clinical Pharmacogenomics Implementation Consortium. CPIC: Implementation. 2022. https://cpicpgx.org/implementation/
- Duarte JD, Dalton R, Elchynski AL, et al. Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing. Genet Med. 2021;23(12):2335–2341. doi:10.1038/s41436-021-01269-9.
- Ramsey LB, Prows CA, Zhang K, et al. Implementation of pharmacogenetics at cincinnati children’s hospital medical center: lessons learned over 14 years of personalizing medicine. Clin Pharmacol Ther. 2019;105(1):49–52. doi:10.1002/cpt.1165.
- Scott SA, Scott ER, Seki Y, et al. Development and analytical validation of a 29 gene clinical pharmacogenetic genotyping panel: multi-Ethnic allele and copy number variant detection. Clin Transl Sci. 2021;14(1):204–213. doi:10.1111/cts.12844.
- Levy KD, Decker BS, Carpenter JS, et al. Prerequisites to implementing a pharmacogenomics program in a large health-care system. Clin Pharmacol Ther. 2014;96(3):307–309. doi:10.1038/clpt.2014.101.
- Salloum RG, Bishop JR, Elchynski AL, et al. Best–worst scaling methodology to evaluate constructs of the consolidated framework for implementation research: application to the implementation of pharmacogenetic testing for antidepressant therapy. Implement Sci Commun. 2022;3(1):52. doi:10.1186/s43058-022-00300-7.
- Wake DT, Smith DM, Kazi S, et al. Pharmacogenomic clinical decision support: a review, how‐to guide, and future vision. Clin Pharmacol Ther. 2022;112(1):44–57. doi:10.1002/cpt.2387.
- Smith DM, Wake DT, Dunnenberger HM. Pharmacogenomic clinical decision support: a scoping review. Clin Pharmacol Ther. 2023;113(4):803–815. doi:10.1002/cpt.2711.
- Blout Zawatsky CL, Leonhard JR, Bell M, et al. Workforce considerations when building a precision medicine program. J Pers Med. 2022;12(11):1929. doi:10.3390/jpm12111929.
- Duong B. Realities of pharmacogenomic and minimizing misconceptions and medication misadventures. Dela J Public Health. 2021;7(5):12–15. doi:10.32481/djph.2021.12.006.
- Aquilante CL, Kao DP, Trinkley KE, et al. Clinical implementation of pharmacogenomics via a health system-wide research biobank: the university of Colorado experience. Pharmacogenomics. 2020;21(6):375–386. doi:10.2217/pgs-2020-0007.
- Cavallari LH, Weitzel KW, Elsey AR, et al. Institutional profile: university of Florida health personalized medicine program. Pharmacogenomics. 2017;18(5):421–426. doi:10.2217/pgs-2017-0028.
- Shuldiner AR, Palmer K, Pakyz RE, et al. Implementation of pharmacogenetics: the university of Maryland personalized anti-platelet pharmacogenetics program. Am J Med Genet C Semin Med Genet. 2014;166C(1):76–84. doi:10.1002/ajmg.c.31396.
- Liu M, Vnencak‐Jones CL, Roland BP, et al. A tutorial for pharmacogenomics implementation through end‐to‐end clinical decision support based on ten years of experience from PREDICT. Clin Pharmacol Ther. 2021;109(1):101–115. doi:10.1002/cpt.2079.
- Gammal RS, Mayes J, Caudle KE. Ready or not, here it comes: direct-to-consumer pharmacogenomic testing and its implications for community pharmacists. J Am Pharm Assoc (2003). 2019;59(5):646–650. doi:10.1016/j.japh.2019.06.008.
- Lu M, Lewis CM, Traylor M. Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe. BMC Med Genomics. 2017;10(1):47. doi:10.1186/s12920-017-0283-0.
- Invitae, Invitae: Precise Medication Management. 2023. https://www.invitae.com/en/providers/medication-management?gclid=Cj0KCQiAiJSeBhCCARIsAHnAzT_DpvVVXzIGjyEaCvpNbb_SQLRKBoksdIYW6ZM2mc5kcg14rjxcyREaAvFREALw_wcB
- 23andMe, 23andMe Pharmacogenetics Reports. 2023. https://www.23andme.com/test-info/pharmacogenetics/
- Mosley SA, Hicks JK, Portman DG, et al. Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial. Contemp Clin Trials. 2018;68:7–13. doi:10.1016/j.cct.2018.03.001.
- Brunette CA, Miller SJ, Majahalme N, et al. Pragmatic trials in genomic medicine: the integrating pharmacogenetics in clinical care (I-PICC) study. Clin Transl Sci. 2020;13(2):381–390. doi:10.1111/cts.12723.
- Reizine N, Vokes EE, Liu P, et al. Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial. Ther Adv Med Oncol. 2020;12:1758835920974118. doi:10.1177/1758835920974118.
- Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol. 2009;62(5):464–475. doi:10.1016/j.jclinepi.2008.12.011.
- Cavallari LH, Cicali E, Wiisanen K, et al. Implementing a pragmatic clinical trial to tailor opioids for acute pain on behalf of the IGNITE ADOPT PGx investigators. Clin Transl Sci. 2022;15(10):2479–2492. doi:10.1111/cts.13376.
- Truong TM, Apfelbaum J, Shahul S, et al. The ImPreSS trial: implementation of point-of-Care pharmacogenomic decision support in perioperative care. Clin Pharmacol Ther. 2019;106(6):1179–1183. doi:10.1002/cpt.1567.
- Reizine NM, Danahey K, Truong TM, et al. Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing. Cancer. 2022;128(8):1649–1657. doi:10.1002/cncr.34104.
- Ray T. Cancer Centers Nudge Oncologists Toward DPYD Testing as PGx Supporters Push For Guidelines Change. 2022. https://www.precisionmedicineonline.com/regulatory-news-fda-approvals/cancer-centers-nudge-oncologists-toward-dpyd-testing-pgx-supporters
- Cohen JK. UCSF Health Set to Launch Clinical Pharmacogenetics Program. 2023. https://www.genomeweb.com/policy-legislation/uk-report-urges-widespread-nhs-uptake-pharmacogenomics#:∼:text=UK%20Report%20Urges%20Widespread%20NHS%20Uptake%20of%20Pharmacogenomics,-. Mar%2029%2C%202022&text=The%2051%2Dpage%20report%2C%20entitled,pharmacogenomic%20testing%20throughout%20the%20UK
- Zakinova A, Long-Boyle JR, French D, et al. A practical first step using needs assessment and a survey approach to implementing a clinical pharmacogenomics consult service. J Am Coll Clin Pharm. 2019;2(3):214–221. doi:10.1002/jac5.1062.
- Accelerating genomic medicine in the NHS. 2022. https://www.england.nhs.uk/long-read/accelerating-genomic-medicine-in-the-nhs/
- UK Report Urges Widespread NHS Uptake of Pharmacogenomics. 2022. https://www.genomeweb.com/policy-legislation/uk-report-urges-widespread-nhs-uptake-pharmacogenomics#:∼:text=UK%20Report%20Urges%20Widespread%20NHS%20Uptake%20of%20Pharmacogenomics,-Mar%2029%2C%202022&text=The%2051%2Dpage%20report%2C%20entitled,pharmacogenomic%20testing%20throughout%20the%20UK
- Royal College of Physicians. Personalised prescribing: using pharmacogenomics to improve patient outcomes. 2022. https://www.rcp.ac.uk/projects/outputs/personalised-prescribing-using-pharmacogenomics-improve-patient-outcomes
- Truong TM, Apfelbaum JL, Danahey K, et al. Pilot findings of pharmacogenomics in perioperative care: initial results from the first phase of the ImPreSS trial. Anesth Analg. 2022;135(5):929–940. doi:10.1213/ANE.0000000000005951.
- O'Donnell PH, Bush A, Spitz J, et al. The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin Pharmacol Ther. 2012;92(4):446–449. doi:10.1038/clpt.2012.117.
- O'Donnell PH, Danahey K, Jacobs M, et al. Adoption of a clinical pharmacogenomics implementation program during outpatient care-initial results of the university of chicago “1,200 patients project. Am J Med Genet C Semin Med Genet. 2014;166C(1):68–75. doi:10.1002/ajmg.c.31385.
- O'Donnell PH, Wadhwa N, Danahey K, et al. Pharmacogenomics-Based point-of-Care clinical decision support significantly alters drug prescribing. Clin Pharmacol Ther. 2017;102(5):859–869. doi:10.1002/cpt.709.
- Friedman PN, Shaazuddin M, Gong L, et al. The account consortium: a model for the discovery, translation, and implementation of precision medicine in african americans. Clin Transl Sci. 2019;12(3):209–217. doi:10.1111/cts.12608.
- Saulsberry L, Danahey K, Middlestadt M, et al. Applicability of pharmacogenomically guided medication treatment during hospitalization of at-Risk minority patients. J Pers Med. 2021;11(12):1343. doi:10.3390/jpm11121343.
- An evidence framework for genetic testing. Washington (DC): National Academies Press; 2017. doi:10.17226/24632.
- Loudon K, Treweek S, Sullivan F, et al. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015;350(may08 1):h2147–h2147. doi:10.1136/bmj.h2147.
- Ginsburg GS, Cavallari LH, Chakraborty H, et al. Establishing the value of genomics in medicine: the IGNITE pragmatic trials network. Genet Med. 2021;23(7):1185–1191. doi:10.1038/s41436-021-01118-9.
- Smith DM, Weitzel KW, Elsey AR, et al. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. Genet Med. 2019;21(8):1842–1850. doi:10.1038/s41436-018-0431-8.
- Lurie JD, Morgan TS. Pros and cons of pragmatic clinical trials. J Comp Eff Res. 2013;2(1):53–58. doi:10.2217/cer.12.74.
- Patsopoulos NA. A pragmatic view on pragmatic trials. Dialogues Clin Neurosci. 2011;13(2):217–224. doi:10.31887/DCNS.2011.13.2/npatsopoulos.
- College of American Pathologists. Molecular Pathology Checklist, CAP Accreditation Program. 2021.
- U.S. Food and Drug Administration, Technology Assessment. Quality, Regulation and Clinical Utility of Laboratory-developed Molecular Tests, Rockville, 2010.
- U.S. Food and Drug Administration. FDA authorizes first direct-to-consumer test for detecting genetic variants that may be associated with medication metabolism. 2018. https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-direct-consumer-test-detecting-genetic-variants-may-be-associated-medication
- College of American Pathologists. Laboratory General Checklist. CAP Accreditation Program. 2021.
- Kellogg M. Return of a Classic: verifying Assay Performance for FDA-approved Methods. CLN Daily. 2017.
- Reizine N, Danahey K, Schierer E, et al. Impact of CYP2D6 pharmacogenomic status on pain control among Opioid-Treated oncology patients. Oncologist. 2021;26(11):e2042–e2052. doi:10.1002/onco.13953.
- Christian C, Borden BA, Danahey K, et al. Pharmacogenomic-Based decision support to predict adherence to medications. Clin Pharmacol Ther. 2020;108(2):368–376. doi:10.1002/cpt.1838.
- Jhun EH, Apfelbaum JL, Dickerson DM, et al. Pharmacogenomic considerations for medications in the perioperative setting. Pharmacogenomics. 2019;20(11):813–827. doi:10.2217/pgs-2019-0040.
- Taylor C, Crosby I, Yip V, et al. A review of the important role of CYP2D6 in pharmacogenomics. Genes (Basel). 2020;11(11):1295. doi:10.3390/genes11111295.
- PharmGKB, Drug Label Annotations. 2023. https://www.pharmgkb.org/gene/PA128/labelAnnotation
- Bank PCD, Swen JJ, Guchelaar H-J. Implementation of pharmacogenomics in everyday clinical settings. 2018. pp. 219–246. doi:10.1016/bs.apha.2018.04.003.
- Caudle KE, Gammal RS, Whirl-Carrillo M, et al. Evidence and resources to implement pharmacogenetic knowledge for precision medicine. Am J Health Syst Pharm. 2016;73(23):1977–1985. doi:10.2146/ajhp150977.
- Bank PCD, Caudle KE, Swen JJ, et al. Comparison of the guidelines of the clinical pharmacogenetics implementation consortium and the dutch pharmacogenetics working group. Clin Pharmacol Ther. 2018;103(4):599–618. doi:10.1002/cpt.762.
- Yoon DY, Lee S, Ban MS, et al. Pharmacogenomic information from CPIC and DPWG guidelines and its application on drug labels. Transl Clin Pharmacol. 2020;28(4):189–198. doi:10.12793/tcp.2020.28.e18.
- Whirl-Carrillo M, Huddart R, Gong L, et al. An Evidence-Based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2021;110(3):563–572. doi:10.1002/cpt.2350.
- Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414–417. doi:10.1038/clpt.2012.96.
- PharmKGB. Clinical annotation levels of evidence. 2023. https://www.pharmgkb.org/page/clinAnnLevels
- Centers for Medicare & Medicaid Services, Billing and Coding: MolDx: Pharmacogenomics Testing. 2023. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=57384
- Danahey K, Borden BA, Furner B, et al. Simplifying the use of pharmacogenomics in clinical practice: building the genomic prescribing system, J Biomed Inform. 75 2017) 110–121. doi:10.1016/j.jbi.2017.09.012.
- CPIC. CPIC: Prioritization. 2023. https://cpicpgx.org/prioritization/#flowchart
- Zhu Y, Moriarty JP, Swanson KM, et al. A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none? Genet Med. 2021;23(3):461–470. doi:10.1038/s41436-020-00995-w.
- Bielinski SJ, Olson JE, Pathak J, et al. Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time—using genomic data to individualize treatment protocol. Mayo Clin Proc. 2014;89(1):25–33. doi:10.1016/j.mayocp.2013.10.021.
- Lopes JL, Harris K, Karow MB, et al. Targeted genotyping in clinical pharmacogenomics. J Mol Diagn. 2022;24(3):253–261. doi:10.1016/j.jmoldx.2021.11.008.
- van der Lee M, Kriek M, Guchelaar HJ, et al. Technologies for pharmacogenomics: a review. Genes (Basel). 2020;11(12):1456. doi:10.3390/genes11121456.
- Schwarz UI, Gulilat M, Kim RB. The role of Next-Generation sequencing in pharmacogenetics and pharmacogenomics. Cold Spring Harb Perspect Med. 2019;9(2):a033027. doi:10.1101/cshperspect.a033027.
- Russell LE, Zhou Y, Almousa AA, et al. Pharmacogenomics in the era of next generation sequencing – from byte to bedside. Drug Metab Rev. 2021;53(2):253–278. doi:10.1080/03602532.2021.1909613.
- Tafazoli A, Guchelaar H-J, Miltyk W, et al. Applying Next-Generation sequencing platforms for pharmacogenomic testing in clinical practice. Front Pharmacol. 2021;12:693453. doi:10.3389/fphar.2021.693453.
- Leung EKY, Agolini E, Pei X, et al. Validation of an extensive CYP2D6 assay panel based on invader and TaqMan copy number assays. J Appl Lab Med. 2017;1(5):471–482. doi:10.1373/jalm.2016.021923.
- Tang NY, Pei X, George D, et al. Validation of a large Custom-Designed pharmacogenomics panel on an array genotyping platform. J Appl Lab Med. 2021;6(6):1505–1516. doi:10.1093/jalm/jfab056.
- Formea CM, Nicholson WT, Vitek CR. An inter-professional approach to personalized medicine education: one institution’s experience. Per Med. 2015;12(2):129–138. doi:10.2217/pme.14.63.
- Formea CM, Nicholson WT, Vitek CR, et al. Implementation of a pharmacogenomics education program for pharmacists. Am J Health Syst Pharm. 2018;75(23):1939–1946. doi:10.2146/ajhp170771.
- Giri J, Curry TB, Formea CM, et al. Education and knowledge in pharmacogenomics: still a challenge? Clin Pharmacol Ther. 2018;103(5):752–755. doi:10.1002/cpt.1019.
- Dodson C. Oncology nurses’ knowledge of pharmacogenomics before and after implementation of an education module. ONF. 2018;45(5):575–580. doi:10.1188/18.ONF.575-580.
- Rohrer Vitek CR, Abul-Husn NS, Connolly JJ, et al. Healthcare provider education to support integration of pharmacogenomics in practice: the eMERGE network experience. Pharmacogenomics. 2017;18(10):1013–1025. doi:10.2217/pgs-2017-0038.
- Bishop JR, Huang RS, Brown JT, et al. Pharmacogenomics education, research and clinical implementation in the state of Minnesota. Pharmacogenomics. 2021;22(11):681–691. doi:10.2217/pgs-2021-0058.
- Hajek C, Hutchinson AM, Galbraith LN, et al. Improved provider preparedness through an 8-part genetics and genomic education program. Genet Med. 2022;24(1):214–224. doi:10.1016/j.gim.2021.08.008.
- Hicks JK, Aquilante CL, Dunnenberger HM, et al. Precision pharmacotherapy: integrating pharmacogenomics into clinical pharmacy practice. J Am Coll Clin Pharm. 2019;2(3):303–313. doi:10.1002/jac5.1118.
- Borden BA, Lee SM, Danahey K, et al. Patient-provider communications about pharmacogenomic results increase patient recall of medication changes. Pharmacogenomics J. 2019;19(6):528–537. doi:10.1038/s41397-019-0076-2.
- Lipschultz E, Danahey K, Truong TM, et al. Creation of a pharmacogenomics patient portal complementary to an existing institutional provider-facing clinical decision support system. JAMIA Open. 2021;4(3):ooab067. doi:10.1093/jamiaopen/ooab067.
- Samwald M, Xu H, Blagec K, et al. Incidence of exposure of patients in the United States to multiple drugs for which pharmacogenomic guidelines are available. PLoS One. 2016;11(10):e0164972. doi:10.1371/journal.pone.0164972.
- Empey PE, Pratt VM, Hoffman JM, et al. Expanding evidence leads to new pharmacogenomics payer coverage. Genet Med. 2021;23(5):830–832. doi:10.1038/s41436-021-01117-w.
- Hefti E, Blanco JG. Documenting pharmacogenomic testing with CPT codes. J Ahima. 2016;87:56–59.
- UnitedHealthcare, pharmacogenetic testing: unitedHealthcare commercial medical policy. 2022.
- Wilkinson E, Connelly D. GPs to start genetic testing patients before prescribing statins, antidepressants and PPIs. Pharmaceutical J. [Internet]. 2022 Oct 27 [cited 2023 Apr 05];News: [5 screens]. Available from: https://pharmaceutical-journal.com/article/news/gps-to-start-genetic-testing-patients-before-prescribing-statins-antidepressants-and-ppis#:∼:text=A%20pilot%20will%20start%20early,The%20Pharmaceutical%20Journal%20has%20learned.